Pyxis Oncology PYXS Stock
Pyxis Oncology Price Chart
Pyxis Oncology PYXS Financial and Trading Overview
| Pyxis Oncology stock price | 3.56 USD |
| Previous Close | 3.02 USD |
| Open | 3.01 USD |
| Bid | 0 USD x 1800 |
| Ask | 0 USD x 900 |
| Day's Range | 2.93 - 3.05 USD |
| 52 Week Range | 1.1 - 6.92 USD |
| Volume | 235.53K USD |
| Avg. Volume | 3.92M USD |
| Market Cap | 115.52M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.59 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.67 USD |
PYXS Valuation Measures
| Enterprise Value | -30952692 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.5487179 |
| PEG Ratio (5 yr expected) | 0.02 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.61974144 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.276 |
Trading Information
Pyxis Oncology Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 27.42% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.92 USD |
| 52 Week Low | 1.1 USD |
| 50-Day Moving Average | 3.25 USD |
| 200-Day Moving Average | 2.21 USD |
PYXS Share Statistics
| Avg. Volume (3 month) | 3.92M USD |
| Avg. Daily Volume (10-Days) | 346.55K USD |
| Shares Outstanding | 38.25M |
| Float | 17.13M |
| Short Ratio | 5.51 |
| % Held by Insiders | 33.28% |
| % Held by Institutions | 53.33% |
| Shares Short | 3.15M |
| Short % of Float | 10.24% |
| Short % of Shares Outstanding | 8.22% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -32.43% |
| Return on Equity (ttm) | -56.30% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -112267000 USD |
| Net Income Avi to Common (ttm) | -108580000 USD |
| Diluted EPS (ttm) | -3.22 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 149.35M USD |
| Total Cash Per Share (mrq) | 4.6 USD |
| Total Debt (mrq) | 20.25M USD |
| Total Debt/Equity (mrq) | 13.31 USD |
| Current Ratio (mrq) | 13.463 |
| Book Value Per Share (mrq) | 4.873 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -88497000 USD |
| Levered Free Cash Flow (ttm) | -74766000 USD |
Profile of Pyxis Oncology
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 150 Cambridgepark Drive |
| ZIP | 02140 |
| Phone | (617) 221-9059 |
| Website | https://pyxisoncology.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 73 |
Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Q&A For Pyxis Oncology Stock
What is a current PYXS stock price?
Pyxis Oncology PYXS stock price today per share is 3.56 USD.
How to purchase Pyxis Oncology stock?
You can buy PYXS shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pyxis Oncology?
The stock symbol or ticker of Pyxis Oncology is PYXS.
Which industry does the Pyxis Oncology company belong to?
The Pyxis Oncology industry is Biotechnology.
How many shares does Pyxis Oncology have in circulation?
The max supply of Pyxis Oncology shares is 62.02M.
What is Pyxis Oncology Price to Earnings Ratio (PE Ratio)?
Pyxis Oncology PE Ratio is now.
What was Pyxis Oncology earnings per share over the trailing 12 months (TTM)?
Pyxis Oncology EPS is -1.59 USD over the trailing 12 months.
Which sector does the Pyxis Oncology company belong to?
The Pyxis Oncology sector is Healthcare.
Pyxis Oncology PYXS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23724.96 USD — |
+0.61
|
9.88B USD — | 23628.82 USD — | 23946.23 USD — | — - | 9.88B USD — |
| US Tech Global Select Market Com NQGS | 11620.1 USD — |
+0.59
|
— — | 11575.56 USD — | 11733.88 USD — | — - | — — |
| US Tech Health Care IXHC | 1115.96 USD — |
+0.87
|
— — | 1099.74 USD — | 1117.62 USD — | — - | — — |
- {{ link.label }} {{link}}